NCT05309668: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05309668 |
|---|---|
| Title | A Phase I/II, Single-Arm, Open Label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 21, 2022 |
| Completion date | Nov. 30, 2027 |
| Required reporting date | Nov. 29, 2028, midnight |
| Actual reporting date | April 1, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |